UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On October 16, 2024, Evoke Pharma, Inc. (the “Company”) entered into the Seventh Amendment to Lease (the “Seventh Amendment”) with SB Corporate Centre III-IV, LLC (the “Landlord”), to amend the Office Lease Agreement, dated as of December 19, 2016, by and between the Landlord and the Company (as amended, the “Lease”), relating to office space located at 420 Stevens Avenue, Suite 230, Solana Beach, California 92075, which serves as the Company’s headquarters. The Seventh Amendment extends the term of the Lease from October 31, 2024 to March 31, 2027. The Seventh Amendment provides that the base monthly rent for the leased space will be $6,456.95 from November 1, 2024 to October 31, 2025, $6,650.66 from November 1, 2025 to October 31, 2026 and $6,850.18 from November 1, 2026 to March 31, 2027, and that the Company will be obligated to pay a specified percentage of certain expenses paid by the Landlord. The Company will also be granted a one-month rent abatement for November 2024, provided there is no material default under the Lease.
The foregoing description of the Seventh Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Seventh Amendment, which will be filed as an exhibit to the Company’s Form 10-K to be filed for the year ended December 31, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
EVOKE PHARMA, INC. |
|
|
|
|
Date: |
October 17, 2024 |
By: |
/s/ Matthew J. D'Onofrio |
|
|
|
Name: Matthew J. D'Onofrio |